RESEARCH ARTICLE

Obesity as an effect modifier of the association between menstrual abnormalities and hypertension in young adult women: Results from Project ELEFANT

Hui Xu¹,², Peng-hui Li³, Timothy M. Barrow⁴, Elena Colicino⁵, Changping Li², Ruixue Song¹,², Hongbin Liu⁶, Nai-jun Tang¹, Songyan Liu⁷, Liqiong Guo¹*, Hyang-Min Byun⁸

¹ Department of Occupational & Environmental Health, School of Public Health, Tianjin Medical University, Tianjin, China, ² Department of Epidemiology and Statistics, School of Public Health, Tianjin Medical University, Tianjin, China, ³ School of Environmental Science and Safety Engineering, Tianjin University of Technology, Tianjin, China, ⁴ Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, United Kingdom, ⁵ Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, ⁶ Tianjin Research Institute for Family Planning, Tianjin, China, ⁷ School of Materials Science and Engineering, Chang’an University, Xi’an, Shanxi, China, ⁸ Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

☯ These authors contributed equally to this work.

* yingqidao@163.com

Abstract

Background

The menstrual cycle is regulated by reproductive hormones such as estrogen which has been implicated in the pathogenesis of hypertension and is associated with obesity. However, to date there has been scant study of hypertension in relation to menstrual characteristics and abnormalities. We hypothesize that adverse menstrual characteristics are associated with an increase the prevalence of hypertension and that this relationship is exacerbated by obesity.

Methods

Our study leverages 178,205 healthy female participants (mean age = 29) in a population-based cross-sectional study in Tianjin, China. Menstrual characteristics including menstrual cycle length and regularity, menstrual bleeding length, menstrual blood loss and dysmenorrhea were assessed by self-reported questionnaires, and hypertension was diagnosed by physician. Multiple logistic regression models were used to assess the relationships between menstrual characteristics and hypertension.

Results

Normal length menstrual cycle (OR = 1.21, 95% CI: 1.03–1.41), oligomenorrhea (OR = 1.54, 95% CI: 1.12–2.07), irregular cycle (OR = 1.54, 95% CI: 1.22–1.93), and light menstrual blood loss (OR = 1.36, 95% CI: 1.06–1.72) were associated with hypertension among
women who are overweight or obese, but not among women who are normal weight. Longer menstrual bleeding duration (OR = 1.44, 95% CI: 1.24–1.67) and dysmenorrhea were associated with increased prevalence of hypertension (OR = 1.20, 95% CI: 1.14–1.41) in all young women.

Conclusions
The prevalence of hypertension is higher among women with menstrual abnormalities, and this association is modified by overweight and obesity.

Introduction
The menstrual cycle is regulated by many different reproductive hormones that are released by the hypothalamus and the pituitary gland [1]. Menstrual abnormalities include painful cramps (dysmenorrhea), heavy bleeding (menorrhagia), absence of menstruation (amenorrhea), light or infrequent menstruation (oligomenorrhea) and premenstrual syndrome (PMS)[2–8]. These can be caused by a range of factors, including hormonal imbalances, genetic factors, infection, stress, and clotting disorders [9, 10], and are associated with complications such as anemia, osteoporosis, and in severe cases, infertility [11]. Abnormal menstrual patterns caused by altered hormonal balance may mediate the risk of hypertension. For example, estrogen can play a role in protecting against cardiovascular diseases (CVDs) including hypertension by vasodilator function [12, 13], while androgens may increase blood pressure and thereby contribute to the pathogenesis of hypertension [14, 15]. Furthermore, many of the known risk factors for menstrual abnormalities, such as weight, age, smoking, family history, pregnancy history and stress [16], are also risk factors for the development of hypertension. However, to date there are few studies that have reported the prevalence of hypertension in women with menstrual abnormalities.

Obesity is associated with increased risk of hypertension, accounting for more than two-thirds of essential hypertension [17]. More than one-third of adults in the world are overweight or obese, and therefore it represents a threat to global health [18]. Furthermore, obesity frequently displays synergy with exposures upon health outcomes, including hypertension. Therefore, obesity could exacerbate the effect of adverse menstrual characteristics to increase the prevalence of hypertension. Hence, here we investigated the association between menstrual abnormalities, including cycle length, regularity, bleeding duration, blood loss and dysmenorrhea, and the prevalence of hypertension (normal, elevated, Stage 1 and Stage 2) in young adult women (n = 178,205). We then examined how obesity modifies the effect of menstrual abnormalities upon the prevalence of hypertension. We report that overweight/obesity amplified the effect of the association between menstrual abnormalities and hypertension in young adults.

Materials and methods
Participants
Project Environmental and LifeStyle FActors in metabolic health throughout life-course Trajectories (ELEFANT) incorporates three population-based studies: Baby (mean age 0), Young (mean age 29) and Elderly ELEFANT (mean age 69). All participants resided in Tianjin (area: 11760 km²), China at the time of recruitment. In this study, we utilized the Young ELEFANT
cohort, using cross-sectional data from 2011–2014. The total number of participants within Young ELEFANT is 356,410 (50% women). Basic demographic and clinical characteristics were measured during routine checkups. The participants also completed questionnaires which assessed lifestyles such as smoking, alcohol consumption, psychological stress, education level, occupation, reproductive characteristics (age at menarche, menstrual cycle length, menstrual bleeding duration, dysmenorrhea and parity), history of disease, familial history of disease, medication use, and others. The protocol of this study was approved by the Institutional Review Board of the Tianjin Medical University before the experiment was started and participants gave written informed consent prior to participation in the study.

Study design
The Young ELEFANT cohort contains a total of 178,205 female participants (Fig 1). We excluded participants with a history of cancer, heart disease, birth defect and participants aged >40 years in order to improve homogeneity of the study population and avoid the instability of menstrual characteristics during pre-menopause. Participants with missing data were also excluded. Following these exclusions, 168,870 participants were included in the final analysis. Furthermore, considering that oral contraception might affect menstrual characteristics, a sensitivity analysis was performed in participants not using the oral contraceptive (n = 167,643).

Assessment of hypertension
After 5 to 10 minutes of rest, individual blood pressure was measured twice in the upper left arm in a seated position using an automatic device (HBP-9021J, Omron, Japan). The blood pressure value was defined as the mean of the two measurements. Hypertension was diagnosed according to the 2017 High Blood Pressure Clinical Practice Guideline [19] and thereby categorized into normal blood pressure (systolic blood pressure (SBP)<120 mm Hg and diastolic blood pressure (DBP)<80 mm Hg), elevated (SBP 120–129 mm Hg and DBP<80 mm Hg), hypertension Stage 1 (SBP 130–139 mm Hg or DBP 80–89 mm Hg), and hypertension Stage 2 (SBP ≥140 mm Hg or DBP≥90 mm Hg).

Assessment of menstrual characteristics
Women reported their usual menstrual cycle characteristics including cycle length, bleeding duration, blood loss, and having dysmenorrhea in the aforementioned questionnaires. The participants reported the upper and lower limit of cycle length and bleeding duration. Irregular cycles were defined as a difference of 7 days or more in cycle length between the upper and lower limits [20]. Polymenorrhea was defined with average cycle of 21 days and oligomenorrhea was having average cycle of 36 days and longer, in line with studies elsewhere [21]. Normal cycle was dichotomized into short normal (>21 and ≤29 days) and long normal (>29 and ≤35 days), as 29 days was the median in the cohort. The normal menstrual bleeding duration ranged between 3 to 7 days [21]. A menstrual pictogram was provided for all participants to evaluate their usual menstrual blood loss [5, 22], with the amount of menstrual blood loss estimated using the images and self-reported usual numbers of sanitary napkins or tampons used, which was categorized as light (<20 mL), medium (20-80mL), and heavy (>80 mL). Dysmenorrhea was defined as crampy and spasmodic pain in lower abdomen radiating to the back and thighs, which begins just before or as menstrual bleeding begins, and gradually diminishes over 1 to 3 days [23].
Assessment of other variables

Data on age at enrollment, education, occupation, lifestyles, family history of disease, reproductive characteristics and medication usage were collected in the interview utilizing a structured questionnaire. Education was calculated by the maximum years of formal schooling and classified into three categories of $\leq 9$, $10-15$ and $\geq 16$ years. Occupation was categorized as manual work, non-manual work or unemployment. According to their registered permanent
residence, the region in which the participants lived was dichotomized into rural and urban. Cigarette smoking (current smokers vs. former or non-smokers), passive smoking (current passive smokers vs. former or non-passive smokers) and alcohol consumption (current drinkers vs. former or non-drinkers) were dichotomized. Psychological stress, including work-related, social and economic stress, was also dichotomized. Parity was dichotomized as one or fewer vs. two or more. The use of oral contraceptive pill was grouped as current, former user and non-user. Family history of hypertension was dichotomized to ‘yes’ or ‘no’. According to a standard protocol, we measured anthropometric measures of each participant, and body mass index (BMI) was calculated as weight/height$^2$ (kg/m$^2$). According to clinical standards in China, overweight was defined as BMI between 24.0 kg/m$^2$ and 28.0 kg/m$^2$ and obesity was as BMI $\geq$ 28.0 kg/m$^2$ [24].

**Statistical analysis**

Characteristics between normotension and hypertension were analyzed with t tests for normal distributive continuous variables, Wilcoxon test for skewed distributive variables and Chi-square tests or Fisher test for categorical variables. Logistic regression analyses were performed to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for hypertension in relation to menstrual characteristics including menstrual cycle (reference group: short normal cycle, of 21–29 days), menstrual bleeding duration (reference group: 3–7 days), menstrual blood loss (reference group: medium) and dysmenorrhea. To understand whether potential confounders could affect the ORs, we adjusted our models for age, BMI, fasting blood glucose level (FBG), smoking status, passive smoking status, alcohol consumption, education, occupation, region, parity, oral contraceptive use, age at menarche and family history of hypertension. The associations between BMI groups were analyzed by healthy weight (18.5 $\leq$ BMI $< 24$) or overweight and obesity (BMI $\geq 24$). We performed the multiplicative interactions between menstrual characteristics and BMI groups inputting the product interaction terms in the logistic regression model adjusting the potential confounders using the likelihood ratio test. Sensitivity analyses were performed with participants not using oral contraception. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC, USA). A two-tailed $p$ value of less than 0.05 was considered to be statistically significant.

**Results**

A total of 168,870 young women were analyzed in this cross-sectional study. Among the young adult women, 6.05% had elevated blood pressure, 30.46% Stage 1 hypertension, and 3.28% Stage 2 hypertension (Table 1). The mean age of the participants was 28 in normotensive group and 30 in Stage 2 hypertension (Table 1).

Menstrual abnormalities including menstrual cycle length, bleeding duration, blood loss and dysmenorrhea were examined with the prevalence of hypertension. The multivariable adjusted models showed that the odds of having Stage 2 hypertension were higher in women with longer menstrual cycle length (>29 and $\leq$35 days: OR 1.14, 95% CI 1.07–1.22; and >35 days: OR 1.50, 95% CI 1.29–1.74) and irregular cycle (OR 1.29, 95% CI 1.26–1.43). The ORs of Stage 2 hypertension were also higher with menstrual bleeding duration of less than 3 days (1.26, 95% CI 1.02–1.54) or longer than 7 days (1.58, 95% CI 1.44–1.72). Young women with menstrual blood loss of $<$20 mL or $>$80mL had significantly higher ORs for Stage 2 hypertension (1.27, 95% CI 1.13–1.41 and 1.41, 95% CI 1.25–1.59, respectively). Young women with dysmenorrhea showed significantly higher OR for Stage 2 hypertension than women without it (1.32, 95% CI 1.25–1.40) (Fig 2). The ORs for elevated blood pressure and Stage 1 hypertension did not increase with menstrual abnormalities, except menstrual blood loss (1.20, 95% CI
Table 1. Basic characteristics of the study population.

| Variables                              | Normotension | Elevated | Stage 1 | Stage 2 | P*  |
|----------------------------------------|--------------|----------|---------|---------|-----|
| Total, n (%)                           | 101671 (60.21%) | 10220 (6.05%) | 51440 (30.46%) | 5539 (3.28%) | <0.0001 |
| Age, years (SD)                        | 28 (4.14)     | 29 (4.28) | 28 (4.39) | 30 (4.51) | 30 (4.78) | 26 (4.78) | 26 (4.78) | <0.0001 |
| BMI, kg/m² (SD)                        | 22 (3.94)     | 23 (4.52) | 23 (3.95) | 24 (4.78) | 26 (4.78) | 26 (4.78) | 26 (4.78) | <0.0001 |
| Overweight, n (%)                      | 15492 (15.24%) | 2163 (21.16%) | 11892 (23.12%) | 1707 (30.82%) | <0.0001 |
| Obesity, n (%)                         | 4500 (4.43%)  | 851 (8.33%) | 4970 (9.66%) | 1526 (27.55%) | <0.0001 |
| SBP, mmHg (SD)                         | 105.91 (6.28) | 121.03 (2.15) | 119.68 (5.56) | 137.75 (14.54) | <0.0001 |
| DBP, mmHg (SD)                         | 67.26 (5.23)  | 71.45 (4.13) | 80.32 (2.08) | 91.84 (9.11) | <0.0001 |
| FBG, mmol/L (SD)                       | 5.00 (0.95)   | 5.11 (1.32) | 5.08 (1.23) | 5.53 (1.91) | <0.0001 |
| Drinking, n (%)                        | 5984 (5.90%)  | 615 (6.03%) | 2682 (5.23%) | 458 (8.30%) | <0.0001 |
| Smoking, n (%)                         | 1183 (1.17%)  | 157 (1.54%) | 550 (1.07%) | 118 (2.14%) | <0.0001 |
| Passive smoking, n (%)                 | 21890 (21.57%) | 2469 (24.19%) | 11301 (22.01%) | 1715 (31.02%) | <0.0001 |
| Education                               |              |          |         |         |     |
| ≤9 years, n (%)                        | 43971 (43.32%) | 4820 (47.31%) | 25327 (49.31%) | 2812 (51.00%) | <0.0001 |
| 10–15 years, n (%)                     | 17536 (17.29%) | 1546 (15.17%) | 7997 (15.57%) | 867 (15.72%) | <0.0001 |
| ≥16 years, n (%)                       | 39965 (39.40%) | 3823 (37.52%) | 18035 (35.12%) | 1835 (33.28%) | <0.0001 |
| Occupation                              |              |          |         |         |     |
| Manual work, n (%)                     | 74328 (73.42%) | 7594 (74.83%) | 39972 (78.00%) | 4122 (74.82%) | <0.0001 |
| Non-manual work, n (%)                 | 22404 (22.13%) | 2085 (20.54%) | 9214 (17.98%) | 1052 (19.10%) | <0.0001 |
| Unemployment, n (%)                    | 4507 (4.45%)  | 470 (4.63%) | 2062 (4.02%) | 335 (6.08%) | <0.0001 |
| Region                                  |              |          |         |         |     |
| Rural, n (%)                           | 73152 (71.94%) | 7427 (72.67%) | 40015 (77.79%) | 3927 (70.90%) | <0.0001 |
| Urban, n (%)                           | 28519 (28.06%) | 2793 (27.33%) | 11425 (22.21%) | 1612 (29.10%) | <0.0001 |
| Psychological stress, n (%)            | 21876 (21.58%) | 2458 (24.08%) | 10436 (20.33%) | 1655 (29.94%) | <0.0001 |
| Oral contraception use, n (%)          | 685 (0.67%)   | 115 (1.13%) | 368 (0.72%) | 59 (1.07%) | <0.0001 |
| Parity                                 |              |          |         |         |     |
| None, n (%)                            | 54922 (54.06%) | 5034 (49.29%) | 26390 (51.33%) | 2495 (45.07%) | <0.0001 |
| ≥1 times, n (%)                        | 46666 (45.94%) | 5180 (50.71%) | 25024 (48.67%) | 3041 (54.93%) | <0.0001 |
| Age at menarche, years (SD)            | 13.85 (1.35)  | 13.87 (1.40) | 13.88 (1.35) | 13.84 (1.62) | 0.0082 |
| Menstrual cycle, days (SD)             | 29.91 (5.24)  | 29.96 (7.14) | 29.89 (5.84) | 30.60 (7.23) | <0.0001 |
| Menstrual cycle                         |              |          |         |         |     |
| Regular cycle, n (%)                   | 94788 (93.26%) | 9664 (94.56%) | 48826 (94.92%) | 5081 (91.73%) | <0.0001 |
| Irregular cycle, n (%)                 | 6883 (6.74%)  | 556 (5.44%) | 2614 (5.08%) | 458 (8.27%) | <0.0001 |
| Menstrual bleeding duration, days (SD) | 5.42 (1.21)   | 5.46 (1.42) | 5.22 (1.21) | 5.62 (1.26) | <0.0001 |
| Menstrual blood loss                   |              |          |         |         |     |
| <20 mL, n (%)                          | 4770 (4.69%)  | 449 (4.39%) | 2252 (4.38%) | 410 (7.40%) | 0.0010 |
| 20-80mL, n (%)                         | 93414 (91.88%) | 9330 (91.29%) | 47145 (91.65%) | 4770 (86.12%) | <0.0001 |
| >80mL, n (%)                           | 3486 (3.43%)  | 441 (4.32%) | 2043 (3.97%) | 359 (6.48%) | <0.0001 |
| Dysmenorrhea, n (%)                    | 42124 (41.44%) | 3769 (36.88%) | 16788 (32.64%) | 2489 (44.94%) | <0.0001 |
| Family history of hypertension, n (%)  | 169 (0.17%)   | 33 (0.32%) | 31 (0.06%) | 7 (0.13%) | <0.0001 |

Continuous variables were expressed by means (SD) and categorical variables were expressed by number (%). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure, T2DM: type 2 diabetes mellitus.

*Comparison between normotension, elevated blood pressure, stage 1 and stage 2 hypertension: p-value from ANOVA, chi-square test or fisher test.

Numbers of subjects with missing value were 306 for passive smoking, 319 for smoke, 483 for drinking, 367 for education, 725 for occupation, 410 for psychological stress, 118 for parity, and 89 for age at menarche.

https://doi.org/10.1371/journal.pone.0207929.t001

1.08–1.33 for elevated and 1.11, 95% CI 1.05–1.17 for Stage 1). The model was adjusted for age at enrollment, smoking, passive smoking, alcohol consumption, BMI, FBG, education,
Menstrual abnormalities and hypertension

The associations between menstrual characteristics including menstrual cycle length, bleeding duration and blood loss and the prevalence of hypertension were different by BMI group (18.5 ≤ BMI < 24, healthy weight vs BMI ≥ 24, overweight and obese) (Tables 3 and 4, related P for interaction is < 0.05). Among healthy weight individuals, the ORs for elevated blood pressure were higher with menstrual cycle length of > 29d and ≤ 35d (1.05, 95% CI 1.00–1.12), menstrual bleeding duration of > 7 days (1.12, 95% CI 1.02–1.23), and menstrual blood loss of > 80 mL (1.25, 95% CI 1.09–1.42). The ORs for Stage 2 hypertension were higher with menstrual bleeding duration of > 7 days (1.36, 95% CI 1.16–1.59) and dysmenorrhea (1.45, 95% CI 1.32–1.59) (Fig 3 and Table 3). Participants with underweight are shown in S1 Table.

However, among overweight and obese women, the ORs of Stage 2 hypertension were significantly higher in participants by most of the menstrual abnormalities, including menstrual cycle length of 29–35 days and > 35 days, irregular cycle, menstrual bleeding duration of > 7 days, menstrual blood loss of > 80 mL and dysmenorrhea (Fig 3 and Table 4). In women with menstrual bleeding duration of > 7 days or menstrual blood loss of > 80 mL, significantly higher ORs were present for Stage 1 hypertension (Table 4).

In the sensitivity analyses after excluding the women who reported using the oral contraceptive pill, we found similar results as when they were included (S2 Table), including when categorized by BMI (S3 Table).
The present study assessed the relationship between menstrual abnormalities with hypertension by blood pressure and the role of obesity in this association in young Chinese women. We

| Table 2. The ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities. | Total n | n | OR (95%CI)* | P_{interaction} |
|---|---|---|---|---|
| **Elevated (n = 10220)** | | | | |
| **Menstrual cycle length** | | | | |
| ≤21d | 369 | 21 | 0.94 (0.58, 1.46) | 0.8837 |
| >21d and ≤29d | 115772 | 6960 | 1.00 (ref) | |
| >29d and ≤35d | 38359 | 2463 | 1.06 (1.01, 1.12) | 0.5049 |
| >35d | 3890 | 220 | 0.91 (0.79, 1.05) | 0.6308 |
| Irregular cycle | 10480 | 556 | 0.82 (0.75, 0.90) | 0.2790 |
| **Menstrual bleeding duration** | | | | |
| <3d | 2040 | 134 | 1.01 (0.84, 1.21) | 0.1910 |
| ≥3d and ≤7d | 153708 | 9221 | 1.00 (ref) | |
| >7d | 13122 | 865 | 1.07 (0.99, 1.16) | 0.8925 |
| **Menstrual blood loss** | | | | |
| <20 mL | 7883 | 449 | 0.87 (0.78, 0.96) | 0.9365 |
| 20-80mL | 154656 | 9330 | 1.00 (ref) | |
| >80mL | 6331 | 441 | 1.20 (1.08, 1.33) | 0.9468 |
| **Dysmenorrhea** | | | | |
| No | 103689 | 6451 | 1.00 (ref) | |
| Yes | 65181 | 3769 | 0.82 (0.75, 0.90) | 0.5372 |
| **Stage 1 (n = 52440)** | | | | |
| **Menstrual cycle length** | | | | |
| ≤21d | 369 | 123 | 1.12 (0.89, 1.40) | 0.4714 |
| >21d and ≤29d | 115772 | 36392 | 1.00 (ref) | |
| >29d and ≤35d | 38359 | 11174 | 0.94 (0.92, 0.97) | 0.0420 |
| >35d | 3890 | 1137 | 0.97 (0.90, 1.04) | 0.0206 |
| Irregular cycle | 10480 | 2614 | 0.74 (0.70, 0.77) | 0.0225 |
| **Menstrual bleeding duration** | | | | |
| <3d | 2040 | 581 | 0.90 (0.81, 1.00) | 0.3369 |
| ≥3d and ≤7d | 153708 | 47278 | 1.00 (ref) | |
| >7d | 13122 | 3581 | 0.95 (0.91, 1.01) | 0.0078 |
| **Menstrual blood loss** | | | | |
| <20 mL | 7883 | 2252 | 0.94 (0.90, 1.00) | 0.5471 |
| 20-80mL | 154656 | 47145 | 1.00 (ref) | |
| >80mL | 6331 | 2043 | 1.11 (1.05, 1.17) | 0.1325 |
| **Dysmenorrhea** | | | | |
| No | 103689 | 35652 | 1.00 (ref) | |
| Yes | 65181 | 16788 | 0.73 (0.71, 0.74) | 0.6994 |
| **Stage 2 (n = 5539)** | | | | |
| **Menstrual cycle length** | | | | |
| ≤21d | 369 | 22 | 1.30 (0.76, 2.02) | 0.3225 |
| >21d and ≤29d | 115772 | 3477 | 1.00 (ref) | |
| >29d and ≤35d | 38359 | 1376 | 1.14 (1.07, 1.22) | 0.5974 |
| >35d | 3890 | 212 | 1.50 (1.29, 1.74) | 0.0268 |
| Irregular cycle | 10480 | 458 | 1.29 (1.16, 1.43) | 0.0946 |
| **Menstrual bleeding duration** | | | | |
| <3d | 2040 | 115 | 1.26 (1.02, 1.54) | 0.4944 |
| ≥3d and ≤7d | 153708 | 4698 | 1.00 (ref) | |
| >7d | 13122 | 726 | 1.58 (1.44, 1.72) | <0.0001 |
| **Menstrual blood loss** | | | | |
| <20 mL | 7883 | 410 | 1.27 (1.13, 1.41) | 0.0217 |
| 20-80mL | 154656 | 4770 | 1.00 (ref) | |
| >80mL | 6331 | 359 | 1.41 (1.25, 1.59) | 0.6142 |
| **Dysmenorrhea** | | | | |
| No | 103689 | 3050 | 1.00 (ref) | |
| Yes | 65181 | 2489 | 1.32 (1.25, 1.40) | 0.2806 |

* Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age at menarche, family history of hypertension.

P_{interaction} is the p value for interaction between BMI and menstrual characteristics.

https://doi.org/10.1371/journal.pone.0207929.t002

### Discussion

The present study assessed the relationship between menstrual abnormalities with hypertension by blood pressure and the role of obesity in this association in young Chinese women. We
found that longer menstrual cycle (>29 days), irregular cycle, light (<20mL) and heavy (>80mL) menstrual blood loss were associated with Stage 2 hypertension among overweight and obese women, but not in normal weight women (BMI ≥24). Longer duration of menstrual bleeding (>7 days) and dysmenorrhea were associated with Stage 2 hypertension irrespective of BMI. Our results suggest that BMI may modify the association between menstrual abnormalities and hypertension in young women.

Table 3. The ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities among young women in who are healthy weight.

| Menstrual cycle length | Total n | Elevated (n = 6551) | Stage 1 (n = 31395) | Stage 2 (n = 2183) |
|------------------------|---------|---------------------|---------------------|---------------------|
| ≤21d                   | 214     | 1.27 (0.71, 2.21)   | 1.32 (0.98, 1.76)   | 2.04 (1.07, 1.29)   |
| >21d and ≤29d          | 78605   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >29d and ≤35d          | 24882   | 1.05 (1.00, 1.12)   | 0.91 (0.88, 0.94)   | 1.05 (0.85, 1.06)   |
| >35d                   | 2218    | 0.85 (0.70, 1.03)   | 0.91 (0.82, 1.00)   | 0.82 (0.52, 1.30)   |
| Irregular cycle        | 6230    | 0.75 (0.66, 0.84)   | 0.67 (0.62, 0.71)   | 0.86 (0.70, 1.06)   |

| Menstrual bleeding duration | Total n | Elevated (n = 6551) | Stage 1 (n = 31395) | Stage 2 (n = 2183) |
|-----------------------------|---------|---------------------|---------------------|---------------------|
| <3d                         | 1237    | 0.98 (0.77, 1.24)   | 0.88 (0.77, 1.01)   | 1.33 (0.93, 1.85)   |
| ≥3d and ≤7d                 | 102771  | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >7d                         | 8141    | 1.12 (1.02, 1.23)   | 0.90 (0.85, 0.95)   | 2.04 (1.16, 1.59)   |

| Menstrual blood loss | Total n | Elevated (n = 6551) | Stage 1 (n = 31395) | Stage 2 (n = 2183) |
|---------------------|---------|---------------------|---------------------|---------------------|
| <20 mL              | 4791    | 0.88 (0.77, 1.00)   | 0.91 (0.85, 1.08)   | 1.05 (0.86, 1.27)   |
| 20-80mL             | 103670  | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >80mL               | 3688    | 1.25 (1.09, 1.42)   | 1.01 (0.94, 1.10)   | 1.08 (0.85, 1.36)   |

| Dysmenorrhea | Total n | Elevated (n = 6551) | Stage 1 (n = 31395) | Stage 2 (n = 2183) |
|--------------|---------|---------------------|---------------------|---------------------|
| No           | 68791   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| Yes          | 43358   | 0.85 (0.80, 0.90)   | 0.69 (0.67, 0.71)   | 1.45 (1.32, 1.59)   |

*Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age at menarche, family history of hypertension.

https://doi.org/10.1371/journal.pone.0207929.t003

Table 4. ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities among young women who are overweight and obese.

| Menstrual cycle length | Total n | Elevated (n = 10220) | Stage 1 (n = 10240) | Stage 2 (n = 5539) |
|------------------------|---------|---------------------|---------------------|---------------------|
| ≤21d                   | 114     | 0.62 (0.21, 1.41)   | 0.95 (0.62, 1.44)   | 1.76 (0.98, 2.98)   |
| >21d and ≤29d          | 28465   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >29d and ≤35d          | 9862    | 1.05 (0.96, 1.16)   | 1.04 (0.99, 1.09)   | 0.84 (0.74, 1.04)   |
| >35d                   | 1315    | 0.97 (0.76, 1.23)   | 1.11 (0.98, 1.26)   | 1.61 (1.34, 1.93)   |
| Irregular cycle        | 3353    | 0.93 (0.80, 1.08)   | 0.91 (0.84, 0.98)   | 0.50 (0.32, 0.70)   |

| Menstrual bleeding duration | Total n | Elevated (n = 10220) | Stage 1 (n = 10240) | Stage 2 (n = 5539) |
|-----------------------------|---------|---------------------|---------------------|---------------------|
| <3d                         | 658     | 1.00 (0.72, 1.36)   | 0.92 (0.77, 1.09)   | 0.91 (0.59, 1.53)   |
| ≥3d and ≤7d                 | 39038   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >7d                         | 3413    | 1.06 (0.91, 1.23)   | 1.08 (1.00, 1.16)   | 1.78 (1.59, 1.99)   |

| Menstrual blood loss | Total n | Elevated (n = 10220) | Stage 1 (n = 10240) | Stage 2 (n = 5539) |
|---------------------|---------|---------------------|---------------------|---------------------|
| <20 mL              | 2294    | 0.88 (0.73, 1.05)   | 1.01 (0.92, 1.11)   | 1.40 (1.22, 1.61)   |
| 20-80mL             | 38682   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| >80mL               | 2133    | 1.15 (0.95, 1.37)   | 1.27 (1.15, 1.40)   | 1.53 (1.33, 1.76)   |

| Dysmenorrhea | Total n | Elevated (n = 10220) | Stage 1 (n = 10240) | Stage 2 (n = 5539) |
|--------------|---------|---------------------|---------------------|---------------------|
| No           | 27545   | 1.00 (ref)          | 1.00 (ref)          | 1.00 (ref)          |
| Yes          | 15564   | 0.80 (0.74, 0.88)   | 0.78 (0.75, 0.82)   | 1.27 (1.17, 1.37)   |

*Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age at menarche, and family history of hypertension.

https://doi.org/10.1371/journal.pone.0207929.t004
### Women with under and normal weight (n=125761)

| Menstrual cycle length | No. of subjects | No. of hypertension | ORs with 95% CIs |
|------------------------|-----------------|---------------------|------------------|
| ≤21d                   | 251             | 3                   | 0.57 (0.14, 1.52) |
| >21d and ≤29d          | 86800           | 1656                | 1.00 (ref)       |
| >29d and ≤35d          | 28241           | 477                 | 0.96 (0.86, 1.07) |
| >35d                   | 2548            | 50                  | 1.10 (0.90, 1.46) |
| Irregular cycle        | 7043            | 104                 | 0.87 (0.71, 1.06) |

### Menstrual bleeding duration

| Menstrual bleeding duration | No. of subjects | No. of hypertension | ORs with 95% CIs |
|-----------------------------|-----------------|---------------------|------------------|
| <3d                         | 1358            | 39                  | 1.38 (0.97, 1.89) |
| ≥3d and ≤7d                 | 113919          | 2029                | 1.00 (ref)       |
| >7d                         | 9606            | 222                 | 1.37 (1.18, 1.59) |

### Menstrual blood loss

| Menstrual blood loss | No. of subjects | No. of hypertension | ORs with 95% CIs |
|---------------------|-----------------|---------------------|------------------|
| <20 mL              | 5491            | 128                 | 1.08 (0.89, 1.30) |
| 20-80 mL            | 115250          | 2077                | 1.00 (ref)       |
| >80 mL              | 4142            | 85                  | 1.07 (0.84, 1.33) |

### Dysmenorrhea

| Dysmenorrhea | No. of subjects | No. of hypertension | ORs with 95% CIs |
|--------------|-----------------|---------------------|------------------|
| No           | 75726           | 1256                | 1.00 (ref)       |
| Yes          | 49157           | 1034                | 1.42 (1.30, 1.55) |

### ORs with 95% CIs for Stage 2 hypertension by menstrual abnormalities in different BMI categories. ORs were adjusted for age at enrollment, smoking, passive smoking, drinking, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, and age at menarche.

https://doi.org/10.1371/journal.pone.0207929.g003
There have been conflicting results from studies investigating the association between menstrual cycle characteristics and hypertension. Irregular menstrual cycles and oligomenorrhea have been reported to be potential markers of CVD risk, including coronary heart disease, in a cohort study of European women, and were also associated with arterial hypertension in a retrospective case-control study of 414 postmenopausal Brazilian women [25, 26]. Longer menstrual cycle length has also been reported to be associated with CVD risk factors such as blood lipid levels and DBP [27]. However, a retrospective case-control study of Chinese women reported no association between menstrual cycle length and hypertension among postmenopausal women [28]. We speculate that these conflicting results may in part be the product of the retrospective studies being conducted in postmenopausal women, thereby potentially being affected by menstrual irregularities during the pre-menopause. Furthermore, obesity has been shown to be significantly associated with having an irregular menstrual cycle. To the best of our knowledge, our study is the largest to examine the association between menstrual cycle characteristics and the prevalence of hypertension, and the first to examine the modifying effect of obesity. We report that oligomenorrhea (36 days and longer), normal prolonged menstrual cycle (29–35 days) and irregular menstrual cycle were each associated with the prevalence of Stage 2 hypertension in young obese women but not in healthy weight women.

The underlying mechanism explaining the relationship between menstrual cycle length and hypertension in obese women is unclear. Lower estrogen levels can lead to a longer or irregular menstrual cycle in women [7, 17]. In addition, these can be the product of inadequate follicular development leading to prolonging of the follicular phase of the cycle, which in itself is often associated with lower average estrogen concentrations [7, 17, 29, 30]. It is known that estradiol (E2) can execute vasodilator function by augmentation of the beta-adrenergic receptor, and reducing oxidative stress [12, 13]. Thus, we speculate that decreased estrogen levels may explain the mechanism underlying the association between irregular or prolonged menstrual cycle length and hypertension. In addition, obese women have much greater amplitudes of changes in sex hormone levels across the menstrual cycle to maintain hormonal homeostasis compared to normal weight women [31]. Adiposity itself can contribute to endothelial or vasodilator dysfunction by production of reactive oxygen species (ROS) and inflammation mediators, similar to lower estrogen levels [32]. Indeed, lower estrogen levels together with increased BMI could bring out apparent impairment of vascular function such as hypertension. This may explain why the association between menstrual cycle and hypertension was only observed among obesity or overweight women.

There have been few previous reports on menstrual bleeding patterns, such as duration and blood loss, with hypertension and CVD. Just as with cycle characteristics, we observed light menstrual blood loss to be associated with increased odds of hypertension only among young women who are overweight or obese, and longer menstrual bleeding duration was also associated with prevalence of hypertension among overweight and obese women. During a normal menstrual period, estrogen levels reduce a few days before the endometrium thickens [33]. If the levels of estrogen are reduced abnormally, this slows the endometrial repair period, contributing to longer bleeding duration and relatively lighter blood loss [34]. Moreover, long bleeding durations are associated with anovulatory cycles which relate to significant reduction in estradiol level [35]. Therefore, it could be that it is changes in estrogen levels that determine the increased prevalence of hypertension among young obese women with longer bleeding duration and lighter blood loss.

Interestingly, dysmenorrhea was shown to be related with increased prevalence of hypertension in both obese and non-obese women in our study. A previous case-control study in Italy reported that the occurrence of pregnancy-related hypertensive disorders including gestational hypertension and preeclampsia is influenced by dysmenorrhea [36]. Compared with
unmenorrheic women, dysmenorrheic women have higher levels of prostaglandins (PGs) in both endometrial biopsies and circulation, predominantly PGF$_{2a}$ and PGE$_2$ [6], and PGF$_{2a}$ is known to elevate blood pressure via vasoconstrictor function [35]. The mechanism underlying this association requires further study.

Several limitations need to be acknowledged. Firstly, information on menstrual cycle were self-reported by the participants, and therefore recall bias can be present. Although, questionnaire data has been reported to be more accurate among younger participants [25, 37], response bias has been a key issue in many studies using self-assessed questionnaire data. Recalibration of response bias has been suggested, however this can cause 'response-shift bias' or other types of response bias [38]. Furthermore, this also requires data from multiple measures and observations [38], which was not available for our analysis. Secondly, due to lack of long-term follow-up data, we cannot infer causality of hypertension with menstrual characteristics. Thirdly, non-steroidal anti-inflammatory drugs (NSAIDs) can be used to alleviate the symptoms of dysmenorrhea, and their chronic usage has been linked with hypertension [39]. However, there is currently no data on NSAID usage within this cohort, and therefore we have been unable to exclude their confounding effect. Indeed, cross-sectional studies such as ours are prone to confounding due to the wide range of factors that may be associated with the outcome. We therefore sought to counter this by adjusting our model for a number of factors known to be associated with hypertension and for which data was available within the cohort (e.g. age, BMI, smoking, fasting blood glucose levels, familial history of the disease), but we cannot exclude the possibility of residual confounding. Finally, the absence of a similarly-sized population study precluded the validation of our findings in an independent cohort. Nonetheless, our study contains several strengths. Firstly, our study has a large sample size and extensive data on menstrual characteristics [26], which we leveraged to comprehensively analyze the relationship between menstrual characteristics and hypertension. Secondly, the age range of our participants was narrow, and the relatively young age of the participants meant we were able to avoid the instability of menstrual characteristics during pre-menopause. Thirdly, we were able to control for a large number of possible confounders, including the use of oral contraceptive.

Conclusions

In conclusion, using a large cross-sectional study based in China, we report that menstrual abnormalities, including menstrual cycle length, blood loss, bleeding duration and dysmenorrhea were associated with Stage 2 hypertension, and that this association interacts with overweight and obesity. Further investigation is required to confirm our findings in independent cohorts and elucidate the biological mechanism(s) behind these associations through laboratory-based experiments.

Supporting information

S1 Table. The ORs with 95% CIs for elevated, stage 1 and stage 2 hypertension by menstrual abnormalities among young women in who are underweight. *Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, oral contraceptive use, age at menarche, family history of hypertension.

S2 Table. The odds ratios (ORs) with 95% confidence intervals (95% CIs) for stage 2 hypertension by menstrual characteristics only women without using oral contraceptive.
Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, age at menarche, family history of hypertension.

(S3 Table) The odds ratios (ORs) with 95% confidence intervals (95% CIs) for stage 2 hypertension by menstrual abnormalities in different BMI levels among young women without using oral contraceptive. Adjusted for age at enrollment, smoking, passive smoking, drinking, BMI, FBG, education, occupation, region, psychological stress, parity, age at menarche, family history of hypertension.

\( P_{\text{interaction}} \) is the p value for interaction between BMI and menstrual characteristics.

Author Contributions

**Conceptualization:** Liqiong Guo, Hyang-Min Byun.

**Data curation:** Elena Colicino.

**Formal analysis:** Hui Xu, Changping Li, Ruixue Song.

**Methodology:** Elena Colicino.

**Resources:** Peng-hui Li, Hongbin Liu, Nai-jun Tang, Songyan Liu.

**Supervision:** Liqiong Guo, Hyang-Min Byun.

**Writing – original draft:** Timothy M. Barrow, Hyang-Min Byun.

**Writing – review & editing:** Timothy M. Barrow, Elena Colicino, Changping Li, Ruixue Song, Hongbin Liu, Nai-jun Tang, Songyan Liu, Liqiong Guo, Hyang-Min Byun.

References

1. Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med. 2010; 363(4):365–71. https://doi.org/10.1056/NEJMc0912024 PMID: 20660404.

2. De Sanctis V, Soliman AT, Elsedfy H, Soliman NA, Soliman R, El Kholy M. Dysmenorrhea in adolescents and young adults: a review in different country. Acta Biomed. 2017; 87(3):233–46. PMID: 28112688.

3. Quinn SD, Higham J. Outcome measures for heavy menstrual bleeding. Womens Health (Lond). 2016; 12(1):21–6. https://doi.org/10.2217/whe.15.85 PMID: 26693585; PubMed Central PMCID: PMCPMC5779559.

4. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. Am Fam Physician. 2006; 73(8):1374–82. PMID: 16669559.

5. Dasharathy SS, Mumford SL, Pollack AZ, Perkins NJ, Mattison DR, Wactawski-Wende J, et al. Menstrual bleeding patterns among regularly menstruating women. American journal of epidemiology. 2012; 175(6):S36–45. https://doi.org/10.1093/aje/kwr356 PMID: 22350580; PubMed Central PMCID: PMCPMC3299419.

6. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Human reproduction update. 2015; 21(6):762–78. https://doi.org/10.1093/humupd/dmv039 PMID: 26946058.

7. Mumford SL, Steiner AZ, Pollack AZ, Perkins NJ, Filiberto AC, Albert PS, et al. The utility of menstrual cycle length as an indicator of cumulative hormonal exposure. The Journal of clinical endocrinology and metabolism. 2012; 97(10):E1871–B. https://doi.org/10.1210/jc.2012-1350 PMID: 22837188; PubMed Central PMCID: PMCPMC3674299.

8. Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet. 1988; 1(8590):870–2. PMID: 2895373.
9. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocrine reviews. 1987; 8(2):132–41. https://doi.org/10.1210/edrv-8-2-132 PMID: 3301317.

10. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British medical journal. 1986; 293(6543):355–9. PMID: 3089520; PubMed Central PMCID: PMC1341046.

11. Zhang Q, Wang YY, Zhang Y, Zhang HG, Yang Y, He Y, et al. The influence of age at menarche, menstrual cycle length and bleeding duration on time to pregnancy: a large prospective cohort study among rural Chinese women. BJOG: an international journal of obstetrics and gynaecology. 2017. https://doi.org/10.1111/1471-0528.14469 PMID: 28128508.

12. Charkoudian N, Hart ECJ, Barnes JN, Joyner MJ. Autonomic control of body temperature and blood pressure: influences of female sex hormones. Clinical autonomic research: official journal of the Clinical Autonomic Research Society. 2017; 27(3):149–55. https://doi.org/10.1007/s10286-017-0420-z PMID: 28488202.

13. Schisterman EF, Gaskins AJ, Mumford SL, Browne RW, Yeung E, Trevisan M, et al. Influence of endogenous reproductive hormones on F2-isoprostane levels in premenopausal women: the BioCycle Study. American journal of epidemiology. 2010; 172(4):430–9. https://doi.org/10.1093/aje/kwq131 PMID: 20679069; PubMed Central PMCID: PMC2950793.

14. Kische H, Gross S, Wallaschofski H, Volzke H, Dorr M, Nauck M, et al. Clinical correlates of sex hormones in women: the study of health in Pomerania. Metabolism: clinical and experimental. 2016; 65(9):1286–96. https://doi.org/10.1016/j.metabol.2016.05.011 PMID: 27506736.

15. Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. Am Fam Physician. 2007; 75(12):1813–9. PMID: 17619523.

16. Landgren BM, Unden AL, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta endocrinologica. 1980; 94(1):89–98. PMID: 6770571.

17. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015; 33(7):673–89. https://doi.org/10.1007/s40273-014-0243-x PMID: 25471927; PubMed Central PMCID: PMC4859313.

18. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertility and sterility. 2001; 76(1):125–31. PMID: 11438330.

21. Yencilek F, Attar R, Erol B, Narin R, Aydin H, Karateke A, et al. Factors affecting sexual function in premenopausal age women with type 2 diabetes: a comprehensive study. Fertility and sterility. 2010; 94(5):1840–3. https://doi.org/10.1016/j.fertnstert.2009.10.060 PMID: 20074725.

22. Wyatt KM, Dimmock PW, Walker TJ, O'Brien PM. Determination of total menstrual blood loss. Fertility and sterility. 2001; 76(1):125–31. PMID: 11438330.

23. Zarei S, Mohammad-Alizadeh-Charandabi S, Mirghafourvand M, Javadzadeh Y, Effati-Daryani F. Effects of Calcium-Vitamin D and Calcium-Alone on Pain Intensity and Menstrual Blood Loss in Women with Primary Dysmenorrhea: A Randomized Controlled Trial. Pain medicine. 2017; 18(1):12–13. https://doi.org/10.1111/pm.12270 PMID: 24163265.

24. Chen C, Lu FC, Department of Disease Control Ministry of Health PRC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomedical and environmental sciences: BES. 2004; 17 Suppl:1–36. PubMed PMID: 15807475.

25. Gast GC, Grobbebe DE, Smit HA, Bueno-de-Mesquita HB, Samsioe GN, van der Schouw YT. Menstrual cycle characteristics and risk of coronary heart disease and type 2 diabetes. Fertility and sterility. 2010; 94(6):2379–81. https://doi.org/10.1016/j.fertnstert.2010.03.044 PMID: 20451189.

26. Azevedo GD, Duarte JM, Souza MO, Costa ESTD, Soares EM, Maranhao TM. Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years. Arquivos brasileiros de endocrinologia e metabolologia. 2006; 50(5):876–83. PMID: 17160211.

27. Matthews KA, Santoro N, Lasley B, Chang Y, Crawford S, Pasternak RC, et al. Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive...
hormones in the follicular and luteal phases. The Journal of clinical endocrinology and metabolism. 2006; 91(5):1789–95. https://doi.org/10.1210/jc.2005-1057 PMID: 16492698.

28. Xu B, Chen Y, Xiong J, Lu N, Tan X. Association of Female Reproductive Factors with Hypertension, Diabetes and LQTC in Chinese Women. Scientific reports. 2017; 7:42803. https://doi.org/10.1038/srep42803 PubMed Central PMCID: PMC5314360. PMID: 28211485

29. Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA)2000.

30. Windham GC, Elkin E, Fenster L, Weller K, Anderson M, Mitchell PR, et al. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology. 2002; 13(6):675–84. https://doi.org/10.1097/01.EDE.0000032361.84313.F2 PMID: 12410009.

31. Yeung EH, Zhang C, Albert PS, Mumford SL, Ye A, Perkins NJ, et al. Adiposity and sex hormones across the menstrual cycle: the BioCycle Study. International journal of obesity. 2013; 37(2):237–43. https://doi.org/10.1038/ijo.2012.9 PMID: 22310471; PubMed Central PMCID: PMC3641001.

32. Engin A. Endothelial Dysfunction in Obesity. Advances in experimental medicine and biology. 2017; 960:345–79. https://doi.org/10.1007/978-3-319-48382-5_15 PMID: 2858207.

33. Maybin JA, Critchley HO. Steroid regulation of menstrual bleeding and endometrial repair. Reviews in endocrine & metabolic disorders. 2012; 13(4):253–63. https://doi.org/10.1007/s11154-012-9228-2 PMID: 23224720.

34. Maybin JA, Critchley HO. Menstrual physiology: implications for endometrial pathology and beyond. Human reproduction update. 2015; 21(6):748–61. https://doi.org/10.1093/humupd/dmv038 PMID: 26253932; PubMed Central PMCID: PMC4594618.

35. Hambridge HL, Mumford SL, Mattison DR, Ye A, Pollack AZ, Bloom MS, et al. The influence of sporadic anovulation on hormone levels in ovulatory cycles. Human reproduction. 2013; 28(6):1687–94. https://doi.org/10.1093/humrep/det090 PMID: 23589536; PubMed Central PMCID: PMC3657125.

36. Fruscalzo A, Bertozzi S, Londero AP, Biasioli A, Driul L, Kiesel L, et al. Menstrual abnormalities and predisposition to pregnancy-related hypertensive disorders: a retrospective study. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2010; 26 (6):445–50. https://doi.org/10.1080/09513591003632092 PMID: 20170353.

37. Jukic AM, Weinberg CR, Wilcox AJ, McConnaughey DR, Hornsby P, Baird DD. Accuracy of reporting of menstrual cycle length. American journal of epidemiology. 2008; 167(1):25–33. https://doi.org/10.1093/aje/kwm265 PMID: 17928401; PubMed Central PMCID: PMC3693484.

38. Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. Int J Behav Healthc Res. 2011; 2(4):320–32. https://doi.org/10.1504/IJBHR.2011.043414 PMID: 25383095; PubMed Central PMCID: PMCPMC4224297.

39. Jurca SJ, Elliott WJ. Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects. Current hypertension reports. 2016; 18(10):73. https://doi.org/10.1007/s11906-016-0682-1 PMID: 27671491.